Business Wire

MA-VERACODE

21.4.2022 17:52:05 CEST | Business Wire | Press release

Share
Veracode Named a Leader in the 2022 Gartner® Magic Quadrant™ for Application Security Testing for Ninth Consecutive Time

Veracode , a leading global provider of application security testing (AST) solutions, today announced it has been positioned as a Leader for the ninth consecutive time in the 2022 Gartner Inc. Magic Quadrant for Application Security Testing1 . The company is the only vendor recognized as a Leader every single year since the report was first published.

“Since Veracode launched in 2006, we have played a significant role in shaping the application security market,” said Sam King, Chief Executive Officer at Veracode. “To be recognized as a Leader every single year, in our opinion, is a validation of our rich heritage, continued innovation, and strong vision for the future of software security and development. With cybersecurity taking center stage for enterprises across all industries, we’re proud to be a trusted partner for our customers, enabling them to bring development and security teams together to build and deliver secure software at the speed that business demands.”

According to Gartner, Veracode is recognized for its completeness of vision and ability to execute in the AST market. The company has also been identified in Gartner Peer Insights™ as a Customers’ Choice for Application Security Testing 2 , which is based on feedback and ratings from independent customer reviews.

Brian Roche, Chief Product Officer at Veracode, said, “The rapid acceleration of digital transformation, combined with increased software supply chain complexity and new cybersecurity regulations, means software security has never been more vital. Over the past year, we have focused heavily on geographical expansion with our European Region instance, and delivered new technologies, such as API Scanning, that address some of our customers’ biggest pain points. Our own platform evolution initiatives give us a deep understanding and appreciation for the challenges many of our customers face in their own digital transformation journeys, improving our capacity to function as a trusted advisor.”

Veracode’s comprehensive platform offers multiple testing types and integrates into popular development tools through a frictionless interface, providing a 360-degree view of application security posture. The company credits its position in the report to a laser focus on the transformation of its platform, launch of API Scanning, authentication management in dynamic analysis, and its static analysis and software composition analysis (SCA) capabilities Veracode’s SCA product uses natural language processing and machine learning to accurately identify vulnerabilities from multiple sources in open-source libraries. Through this proprietary process, the Veracode solution has identified hundreds of previously undetected vulnerabilities in open-source libraries in the last year alone.

In 2021, Veracode launched the Veracode European Region instance to support EU data residency requirements. The underlying platform has been leveraged to underpin Veracode’s much-anticipated FedRAMP instance, which will be introduced in the coming months.

“It’s a truly exciting time for Veracode. We have just announced a significant growth investment from TA Associates with a $2.5 billion valuation—a major milestone in our 16-year history—and look forward to a year of continued innovation and accelerating growth. We remain tirelessly committed to our mission of securing the software that powers our customers’ businesses, and our continued position as a Leader is, in our opinion, a testament to the passion and dedication of our team around the world,” King added.

To download a complimentary copy of the full 2022 Gartner Magic Quadrant Report, visit: https://info.veracode.com/2022-gartner-mq-gated.html

To learn more about application security from Veracode, please visit: https://www.veracode.com/products

1 Gartner, “Magic Quadrant for Application Security Testing” by Dale Gardner, Mark Horvath, Dionisio Zumerle, 18 April 2022. 
2 Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, 27 October 2021.

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Gartner and Peer Insights are trademarks of Gartner, Inc. and/or its affiliates. All rights reserved. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

Gartner Peer Insights Customers’ Choice constitute the subjective opinions of individual end-user reviews, ratings, and data applied against a documented methodology; they neither represent the views of, nor constitute an endorsement by, Gartner or its affiliates.

Gartner and Magic Quadrant are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved

About Veracode

Veracode is a leading AppSec partner for creating secure software, reducing the risk of security breach, and increasing security and development teams’ productivity. As a result, companies using Veracode can move their business, and the world, forward. With its combination of process automation, integrations, speed, and responsiveness, Veracode helps companies get accurate and reliable results to focus their efforts on fixing, not just finding, potential vulnerabilities. Learn more at www.veracode.com , on the Veracode blog and on Twitter .

Copyright © 2022 Veracode, Inc. All rights reserved. All other brand names, product names, or trademarks belong to their respective holders.

Link:

ClickThru

Social Media:

https://www.facebook.com/VeracodeInc/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye